What does dasatinib treat?

Dasatinib (Dasatinib) is an anti-tumor drug mainly used to treat leukemia. Dasatinib is mainly used to treat adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase, accelerated phase and blast phase (blast myeloblastosis and blast phase) who are resistant or intolerant to imatinib mesylate. In addition, it can also be used to treat other types of leukemia, such as acute lymphoblastic leukemia.

Dasatinib is a protein kinase inhibitor that inhibits oncogenic kinases. It reduces the number of damaged white blood cells in the body and helps patients produce more normal cells by inhibiting abnormal proteins such as Bcr/ABL1 and steroid receptor coactivator (SRC) family kinases.

For patients with chronic myelogenous leukemia in the chronic phase, the recommended dose of dasatinib is 100 mg once a day, which can be increased to 140 mg according to circumstances. DasatinibFor patients with advanced chronic myelogenous or lymphocytic leukemia or Ph chromosome-positive acute lymphoblastic leukemia, the initial dose is 70 mg twice daily, which can be increased to 100 mg twice daily.

The clinical efficacy of dasatinib has been confirmed in multiple global clinical trials. It can effectively control the development of the disease, improve the patient's quality of life, and delay the deterioration of the disease. At the same time, dasatinib can also enhance physical fitness and help patients better cope with the disease.

In conclusion, dasatinib is an important anti-tumor drug with significant efficacy in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and other types of leukemia that are resistant or intolerant to imatinib mesylate. When using dasatinib, patients should follow the doctor's guidance and use the medication rationally to achieve the best therapeutic effect.